Patents by Inventor Lars Wortmann
Lars Wortmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083857Abstract: The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 11, 2023Publication date: March 14, 2024Inventors: Lars WORTMANN, Brice SAUTIER, Knut EIS, Hans BRIEM, Niels BOHNKE, Franz VON NUSSBAUM, Roman HILLIG, Benjamin BADER, Jens SCHRODER, Kirstin PETERSEN, Philip LIENAU, Antje Margret WENGNER, Dieter MOOSMAYER, Qiuwen WANG, Hans SCHICK
-
Publication number: 20230201186Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 30, 2022Publication date: June 29, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, Dennis KIRCHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, Dirk KOSEMUND, Rienk OFFRINGA, Mareike GREES
-
Publication number: 20230148194Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: May 11, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Rienk OFFRINGA, Mareike GREES
-
Publication number: 20230062100Abstract: The present invention covers aminoquinolone compounds of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, X and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Julien LEFRANC, Rienk OFFRINGA
-
Publication number: 20230064809Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, m, n, o and p are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, Dennis KIRCHHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Rienk OFFRINGA
-
Publication number: 20230029385Abstract: The present invention covers 2-methyl-aza-quinazoline compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 14, 2020Publication date: January 26, 2023Inventors: Lars WORTMANN, Keith GRAHAM, Benjamin BADER, Roman HILLIG, Jens SCHROEDER, Philip LIENAU, Hans BRIEM
-
Patent number: 11529356Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 21, 2020Date of Patent: December 20, 2022Assignee: Bayer Pharma AktiengesellschaftInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20220274979Abstract: The present invention covers 2-methyl-aza-quinazoline compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredientsType: ApplicationFiled: April 15, 2019Publication date: September 1, 2022Applicants: Bayer Pharma Aktiengesellschaft, Bayer Healthcare ChinaInventors: Lars WORTMANN, Brice SAUTIER, Knut EIS, Hans BRIEM, Niels BÖHNKE, Franz VON NUSSBAUM, Roman HILIG, Benjamin BADER, Jens SCHRÖDER, Kirstin PETERSEN, Philip LIENAU, Antje Margret WENGNER, Dieter MOOSMAYER, Qiuwen WANG, Hans SCHICK
-
Publication number: 20220235013Abstract: The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 19, 2018Publication date: July 28, 2022Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars WORTMANN, Brice SAUTIER, Knut EIS, Hans BRIEM, Niels BOHNKE, Franz VON NUSSBAUM, Roman HILLIG, Benjamin BADER, Jens SCHRODER, Kirstin PETERSEN, Philip LIENAU, Antje Margret WENGNER, Dieter MOOSMAYER, Qiuwen WANG, Hans SCHICK
-
Publication number: 20210017174Abstract: The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 1, 2019Publication date: January 21, 2021Inventors: Duy NGUYEN, Lars WORTMANN, Adelaide Clara FARIA ALVARES DE LEMOS, Ulf BOEMER, Detlev SUELZLE, Simon HOLTON, Christian LECHNER
-
Publication number: 20200383991Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 21, 2020Publication date: December 10, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 10772893Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Patent number: 10729680Abstract: The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: January 6, 2017Date of Patent: August 4, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Marcus Koppitz, Julien Lefranc, Lars Wortmann, Antje Margret Wengner, Gerhard Siemeister, Ulf Bömer, Benjamin Bader, Philip Lienau, Hans Schick
-
Publication number: 20190142812Abstract: The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 6, 2017Publication date: May 16, 2019Inventors: Ulrich LÜCKING, Marcus KOPPITZ, Julien LEFRANC, Lars WORTMANN, Antje Margret WENGNER, Gerhard SIEMEISTER, Ulf BÖMER, Benjamin BADER, Philip LIENAU, Hans SCHICK
-
Publication number: 20180256591Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 8, 2018Publication date: September 13, 2018Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 9993484Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 3, 2015Date of Patent: June 12, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20170216304Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 3, 2015Publication date: August 3, 2017Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 9675612Abstract: The present invention relates to substituted thiazolopyrimidine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: March 3, 2014Date of Patent: June 13, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Klar, Lars Wortmann, Keith Graham, Florian Puehler, Detlev Sülzle, Georg Kettschau, Philip Lienau
-
Patent number: 9556181Abstract: The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of formula I, below, as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients wherein R1a, R1b, R1c, and R2 are defined herein.Type: GrantFiled: January 29, 2014Date of Patent: January 31, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Klar, Lars Wortmann, Georg Kettschau, Florian Pühler, Philip Lienau, Detlev Sülzle
-
Patent number: 9549932Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 19, 2016Date of Patent: January 24, 2017Assignee: Bayer Pharma AktiengesellschaftInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Franz Von Nussbaum, Benjamin Bader, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Dieter Moosmayer, Uwe Eberspächer, Hans Schick, Knut Eis, Marcus Koppitz, Antje Margret Wengner, Joanna Grudzinska-Goebel